Evaluation of the pharmacokinetics and safety of TMC125 [etravirine] administered once and twice-daily and following a 2-week-treatment period with efavirenz in male and female healthy volunteers.

Trial Profile

Evaluation of the pharmacokinetics and safety of TMC125 [etravirine] administered once and twice-daily and following a 2-week-treatment period with efavirenz in male and female healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2009

At a glance

  • Drugs Efavirenz; Etravirine
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Oct 2009 Resutls reported in Journal of Acquired Deficiency Syndromes.
    • 06 Jun 2008 Status change
    • 04 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top